Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: March 22, 2023

Patent: 5,366,728

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Summary for Patent: 5,366,728
Title: Stable forms of antigenic Taenia ovis polypeptides
Abstract:Stable forms of Taenia ovis peptide antigens, such as portions of a T. ovis oncosphere antigen which runs as a 47-52 kDa doublet, are suitable for use in vaccines to protect ruminants against infection by cestode parasites. The antigens are preferably obtained by isolation and expression of the DNA encoding them in recombinant host cells. Aspects of the invention include DNA encoding T. ovis antigens, vectors containing such DNA and host cells which express the T. ovis antigens.
Inventor(s): Harrison; Gavin B. L. (Upper Hutt, NZ), Dempster; Robert P. (Upper Hutt, NZ), Rickard; Michael D. (Werribee, AU), Lightowlers; Marshall W. (Victoria, AU), Heath; David D. (Paremata, NZ), Lawrence; Stephen B. (Upper Hutt, NZ), O\'Hoy; Kim L. (Pascoe Vale, AU)
Assignee: Pitman-Moore New Zealand Limited (Upper Hutt, NZ) The University of Melbourne (Melbourne, AU) Her Majestry the Queen in right of New Zealand through the Ministry of (Wellington, NZ)
Application Number:07/969,450
Patent Claims:see list of patent claims

Details for Patent 5,366,728

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 See Plans and Pricing 2008-01-06
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 See Plans and Pricing 2008-01-06
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 See Plans and Pricing 2008-01-06
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.